Mineralys Therapeutics, Inc.
MLYS

$639.49 M
Marketcap
$12.86
Share price
Country
$-0.73
Change (1 day)
$16.91
Year High
$6.06
Year Low
Categories

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

marketcap

P/B ratio for Mineralys Therapeutics, Inc. (MLYS)

P/B ratio as of 2023: 1.29

According to Mineralys Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.29. At the end of 2022 the company had a P/B ratio of -14.41.

P/B ratio history for Mineralys Therapeutics, Inc. from 2020 to 2023

P/B ratio at the end of each year

Year P/B ratio
2023 1.29
2022 -14.41
2021 -31.42
2020 -200.22